Pharmalittle: Rising Concerns Over Telehealth Fees and Drug Approval Controversies

Another busy day is underway at the Pharmalittle desk. While our official mascots remain occupied with their morning routine, we’re brewing another cup of Earl Gray to power through the day’s updates.

Here’s what’s making headlines:

Telehealth Partnerships Under Scrutiny for High Fees and Potential Kickbacks

As collaborations between pharmaceutical companies and telehealth providers expand, health policy experts and legislators are raising alarms over the substantial fees telehealth companies receive from drugmakers. Critics argue these arrangements may violate federal laws prohibiting financial kickbacks to induce prescribing, potentially leading to uncoordinated care and overprescribing of expensive, branded medications.

The same concerns apply to drug-specific telehealth visit coupons, which drugmakers have long used to encourage patients to opt for high-cost medications. These coupons can influence not only out-of-pocket drug costs but also the price of clinician consultations for prescriptions.

HHS Secretary Kennedy Denies Involvement in FDA’s Rejection of Replimune’s Skin Cancer Drug

Robert F. Kennedy Jr., U.S. Secretary of Health and Human Services, testified before a Senate hearing on Wednesday, stating he had no role in the FDA’s decision to reject Replimune Group Inc.’s advanced skin cancer drug. The FDA declined approval due to concerns over the company’s reliance on a single-arm study without a control group. The agency requested data from a well-controlled trial to demonstrate the drug’s effectiveness.

“This decision comes out of FDA, and we trust the process there. And I’ve been told by Marty Makary, FDA Commissioner, that every panel that looked at that drug unanimously voted against it … because it does not appear to work,” Kennedy stated.

However, an op-ed in The Wall Street Journal disputed Kennedy’s claims, citing cancer doctors involved in the drug’s trials who attested to its effectiveness.